HK Stock MarketDetailed Quotes

FOSUN PHARMA (02196)

Watchlist
  • 17.350
  • +1.150+7.10%
15min DelayNot Open Sep 7 16:07 CST
46.13BMarket Cap11.82P/E (TTM)

About FOSUN PHARMA Company

Founded in 1994, the company is an innovation-driven, global pharmaceutical and healthcare group. Guided by the mission "Enabling Every Family to Enjoy Good Health," we are deeply committed to the pharmaceutical business, with a strong focus on innovative medicines, and have built a comprehensive, end-to-end ecosystem spanning the entire pharmaceutical and healthcare value chain. We operate across multiple segments, including pharmaceuticals—centered on innovative drugs—and direct operations in medical devices and diagnostics, as well as healthcare services. Our key product categories encompass innovative medicines, established products and manufacturing, vaccines; medical aesthetics; respiratory health; specialized medical care; and in vitro diagnostics; along with a range of healthcare services. Corporate accolades include: inclusion on the 2018 World's Best Employers list; ranking among the Top 10 Chinese Pharmaceutical Industry Groups in 2018; placement on the 2018 Asia's Top 50 Listed Companies list; recognition as one of China's Top 100 Pharmaceutical Manufacturers in 2017; inclusion on the 2017 China Pharmaceutical Industry Top 100 list; selection among the 2018 Top 30 High-Quality Private Listed Companies in China; and designation as one of the 2018 Top 30 Responsible Private Listed Companies in China. Additionally, the company was honored by People's Daily Online as a "2023 Outstanding Responsible Enterprise."

Company Profile

Symbol02196
Company NameFOSUN PHARMA
ISINCNE100001M79
Listing DateOct 30, 2012
Issue Price11.80
Shares Offered336.07M share(s)
FoundedMay 31, 1995
Registered AddressChina
Chairmanyuqingguanxiaohui chen
Secretaryxiaoxianchenxiuling dong
Audit InstitutionErnst & Young, Ernst & Young Huaming Certified Public Accountants (Special General Partnership)
Company CategoryMainland registration of Mainland Individuals control
Registered Office9th Floor, No. 510 Caoyang Road, Shanghai
Head Office and Principal Place of Business

Room 1917, 19th Floor, Phase I, Lee Garden, 33 Hysan Road, Causeway Bay, Hong Kong

Fiscal Year Ends12-31
Employees40603
MarketHong Kong motherboard
Phone021-33987870
Fax021-33987871
Emailir@fosunpharma.com
Websitehttp://www.fosunpharma.com
Business

Biochemical products, reagents, biotechnology services; manufacturing and sales of self-developed products; instruments and meters; electronic products; computers; chemical raw materials (excluding hazardous materials); consulting services; export of the company's own manufactured products and related technologies; import of raw and auxiliary materials, machinery and equipment, instruments and meters, spare parts, and related technologies required for the company's production and research activities.

Company Executives

  • Name
  • Position
  • Salary
  • yuqing chen
  • Chairman, Executive Director, Chairman of the Strategy Committee, Members of the Environmental, Social and Governance Committee, Authorized Representative
  • 1.89M
  • xiaohui guan
  • Executive Director, Co-Chairman, Nomination Committee Member, Members of the Environmental, Social and Governance Committee
  • 6.22M
  • deyong wen
  • Vice Director, Executive Director, Senior Vice President
  • 8.55M
  • kexin wang
  • Executive Director, Member of the Strategy Committee
  • 9.71M
  • yi liu
  • Chief Executive Officer, Executive Director
  • 3.75M
  • qiyu chen
  • Non-executive Director, Members of the Strategy Committee, Members of the Remuneration Committee
  • --
  • donghui pan
  • Non-executive Director, Nomination Committee Member, Members of the Remuneration Committee
  • --
  • zishan yu
  • Independent Non-Executive Director, Chairman of the Environmental, Social and Governance Committee, Nomination Committee Member, Members of the Remuneration and Performance Review Committee
  • 400.00K
  • quandi wang
  • Independent Non-Executive Director, Chair of the Nominating Committee, Audit Committee Member, Members of the Environmental, Social and Governance Committee
  • 400.00K
  • Chen Penghui
  • Independent Non-Executive Director, Chair of the Remuneration and Nomination Committee, Audit Committee Member, Members of the Strategy Committee, Nomination Committee Member
  • 175.00K
  • yucheng yang
  • Independent Non-Executive Director, Chair of the Audit Committee, Members of the Remuneration and Performance Review Committee, Members of the Environmental, Social and Governance Committee
  • 175.00K
  • jia yan
  • Employee Director
  • 2.80M
  • jingshu cai
  • Vice President
  • --
  • jing li
  • Co-President
  • --
  • Xingli Wang
  • President
  • --
  • Wenjie Zhang
  • Co-President
  • --
  • rongli feng
  • Chief Executive Officer
  • --
  • donghua wang
  • Senior Vice President
  • --
  • hang hu
  • Senior Vice President
  • --
  • zhanyu chen
  • Senior Vice President
  • --
  • Xiang Li
  • Senior Vice President
  • --
  • xiaoxian dong
  • Vice President, Joint Company Secretary, Director's Secretary
  • --
  • li su
  • Vice President
  • --
  • hao ji
  • Vice President
  • --
  • yue zhu
  • Vice President
  • --
  • zhi huang
  • Senior Vice President, Chief Financial Officer
  • --
  • lilang lv
  • Vice President
  • --
  • fangbing yuan
  • Vice President, Co-Chief Strategy Enablement Officer
  • --
  • lingyuan meng
  • Vice President
  • --
  • xiuling chen
  • Joint Company Secretary, Authorized Representative
  • --
Market Insights
Petroleum
No. Symbol 20D % Chg
Sample Name
Sample Code
 +9.38%
Sample Name
Sample Code
 +6.32%
Sample Name
Sample Code
 +5.41%
4
PETROCHINA
00857
+4.13%
5
CHINA OILFIELD
02883
+2.87%
View More
No. Symbol 20D % Chg
Sample Name
Sample Code
 +24.15%
Sample Name
Sample Code
 +15.35%
Sample Name
Sample Code
 +5.18%
4
China Great Wall Technology Group
000066
+0.54%
5
INESA Intelligent Tech Inc.
600602
-0.06%
View More
China and the US begin implementing the Kuala Lumpur economic and trade consultation consensus.
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More
[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"

- No more -